India 'Privately' Against Patent-overriding Drug Permits: USIBC

US-India Business Council, wants Indian govt to make a public commitment to forego using compulsory licensing for commercial purposes and use this clause for public emergencies.

Published: 09th March 2016 01:05 AM  |   Last Updated: 09th March 2016 01:05 AM   |  A+A-


NEW DELHI: Indian government has "privately reassured" industry lobby group US-India Business Council that the country would not invoke 'compulsory licensing' for commercial purposes that could allow local drugmakers to make cheaper products by overriding patents of big global players.

The US-India Business Council, however, wants the Indian government to make "a public commitment" to forego using compulsory licensing for commercial purposes and use this clause for public emergencies only, the advocacy group has said in a submission to the US Trade Representative.

As per the WTO agreement, a compulsory license can be invoked by a national government to allow someone else to produce a patented product or process without the consent of the patent owner. It is done for the cause of public health.

"Despite compulsory licensing denials, industry continues to be concerned by the potential threat of compulsory licensing. The Government of India has privately reassured...(that) it would not use Compulsory Licenses for commercial purposes," the USIBC said in its submission.

The submission was made last month by USIBC to the Office of the US Trade Representative and is addressed to Acting Assistant United States Trade Representative, Intellectual Property and Innovation Probir Mehta.

It further said that USIBC would be further encouraged if the Government of India made a public commitment to forego using compulsory licensing for commercial purposes and in public emergencies only, saying "it would greatly enhance legal certainty for innovative industries".

No immediate comments were available from the concerned authorities in this regard.

The Indian Patent Office had invoked such a clause for the first time in March 2012 to permit Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a fraction of the price charged by its patent-holder Bayer Corporation.

The order, which provided great relief to the kidney and liver cancer patients, was issued by India Patents Office as a 'Compulsory Licence' under Section 84 of the Indian Patent Act, which is in compliance with the TRIPS agreement of the World Trade Organisation.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp